healthrx.com

Lunesta Cost in Tennessee 2026: Prices, Medicaid, Insurance, and Compounded Options

By
Updated
Prescription access and medication affordability image for Lunesta Cost in Tennessee 2026: Prices, Medicaid, Insurance, and Compounded Options
Image: HealthRX.com clinical image

Direct answer

Eszopiclone (brand name Lunesta, manufactured by Sunovion) is a Schedule IV controlled substance approved by the FDA in December 2004 for the treatment of insomnia, available as immediate-release tablets in 1 mg, 2 mg, and 3 mg strengths taken once nightly [FDA label]. Generic eszopiclone has been available since patent exclusivity ended in 2014, and generic drugs of this kind are typically sold at cash prices well under the brand list price at most U.S. retail chains. Tennessee Medicaid (TennCare) coverage for eszopiclone specifically for insomnia, current commercial insurance tier placement, and specific cash prices at named Tennessee pharmacies are all subject to change and are not independently verified in this article; readers should confirm them with TennCare, their plan's pharmacy benefit manager, or the dispensing pharmacy before relying on any single dollar figure.

What eszopiclone is, and what it is not

Eszopiclone is the generic (nonproprietary) name for the active drug. Lunesta is the original brand name, marketed by Sunovion Pharmaceuticals. Pharmacologically it belongs to the "Z-drug" class of nonbenzodiazepine hypnotics, structurally related to zopiclone, and it works by binding GABA-A receptor sites, similar in mechanism to benzodiazepines but chemically distinct. It is not the same molecule as zolpidem (Ambien) or zaleplon (Sonata), and it should not be confused with orexin receptor antagonists such as suvorexant (Belsomra) or lemborexant (Dayvigo), which work through a different pathway and do not carry the same controlled-substance schedule in every case.

The FDA label documents eszopiclone's approved indication as treatment of insomnia in adults, without the historical short-term-use restriction placed on some older hypnotics, and it carries dosing guidance, hepatic-impairment cautions, and drug-interaction warnings that a prescriber should review with each patient individually FDA label.

Why the price you see varies so much

Brand Lunesta and generic eszopiclone are legally the same active ingredient sold as different commercial products. Brand-name drugs generally carry higher list prices that reflect development, marketing, and exclusivity-period costs; once generic competition enters after patent expiration, prices for a given molecule typically fall substantially, sometimes to a small fraction of the original brand price. Multiple generic manufacturers received FDA approval to market eszopiclone after 2014, and the FDA's Orange Book documents which generic products have been rated therapeutically equivalent to the reference brand FDA Orange Book.

Beyond the brand-versus-generic gap, cash price at any specific Tennessee pharmacy depends on the pharmacy's own markup, dispensing fee, wholesale contract, and whether the patient presents a discount coupon. These factors change frequently and differ store to store, so a single "Tennessee price" cannot be stated as a fixed fact. Coupon aggregator sites and pharmacy price-check tools sometimes advertise generic eszopiclone in the range of roughly ten to twenty-five dollars for a 30-tablet supply, but this article has no live, verifiable pricing feed and these figures should be treated as illustrative starting points, not guaranteed prices, and confirmed at the pharmacy counter on the day of purchase.

Does TennCare (Tennessee Medicaid) cover eszopiclone?

State Medicaid programs, including TennCare, maintain preferred drug lists that are updated periodically, and coverage of a specific sedative-hypnotic for insomnia can be restricted, require prior authorization, or be excluded outright depending on the current formulary version. This article does not have a verified, dated citation to TennCare's current pharmacy preferred drug list, so it cannot state with confidence whether eszopiclone is covered, excluded, or restricted for insomnia as of any specific date in 2025 or 2026. What can be said generally is that state Medicaid programs commonly restrict sedative-hypnotics as a class due to controlled-substance and cost concerns, and that prior authorization is a common route when a covered comorbid diagnosis (such as depression, where insomnia is a documented target symptom in some clinical trial populations) is present.

If you are a TennCare member, the reliable path is to call the TennCare pharmacy help line or check the published preferred drug list directly, and to ask your prescriber whether a covered alternative such as trazodone or doxepin is clinically appropriate if eszopiclone is not covered. Cognitive behavioral therapy for insomnia (CBT-I) is recommended by sleep medicine guidelines as a first-line treatment before medication for chronic insomnia in adults, and may be accessible through a covered behavioral health benefit regardless of the pharmacy formulary dispute.

Commercial insurance and Medicare Part D

Most commercial pharmacy benefit managers place generic drugs on a lower cost-sharing tier than brand-name equivalents, and it is common for plans to require documented step therapy through a different first-line hypnotic before approving a newer or costlier agent. Actual tier placement, copay amount, and step-therapy rules differ by plan, by employer group, and by plan year, and this article does not have a verified source for a specific Tennessee-issued commercial plan's current formulary. If cost is a concern, request your plan's current formulary document or call member services before assuming a copay amount.

Medicare Part D plans are required to follow CMS guidance on formulary design and controlled-substance dispensing rules, described in CMS guidance governing Part D formulary design and controlled-substance dispensing rules. Beneficiaries who reach the coverage gap phase of their Part D benefit pay a percentage of the negotiated price rather than a flat copay; the exact percentage and dollar impact depend on the plan year and should be checked against the current CMS guidance and the beneficiary's own Explanation of Benefits.

Is compounded eszopiclone legal in Tennessee?

Yes, in a specific and limited sense. A licensed 503A compounding pharmacy may prepare an individualized eszopiclone formulation for a named patient from a valid prescription, under the federal framework governing 503A facilities. A compounded product made this way is not FDA-approved as a finished drug product, has not undergone the bioequivalence testing required of an approved generic, and its quality depends on the individual pharmacy's compliance with USP compounding standards and state board oversight. Compounding is typically appropriate when a patient needs a dose strength that commercial manufacturers do not produce, not as a routine substitute for an already-approved, already-inexpensive generic tablet.

Some telehealth or subscription-based prescribing services bundle a compounded medication into a membership fee. Before using such a service, confirm independently that both the prescribing clinician and the dispensing compounding pharmacy hold active Tennessee licenses; a membership fee does not substitute for that verification.

Telehealth prescribing in Tennessee

Tennessee permits telehealth prescribing of controlled substances when the prescriber holds an active Tennessee license and the encounter meets the same standard of care expected of an in-person visit, including a documented sleep history, review of contraindications, and informed consent covering the boxed warning discussed below. Federal DEA telemedicine flexibilities for controlled-substance prescribing without a prior in-person visit have been extended multiple times since the COVID-19 public health emergency ended, and the exact rules in effect at any given date should be confirmed against current DEA guidance rather than assumed from this article, since the regulatory status is actively evolving.

Safety information that applies regardless of price

The FDA added a boxed warning in 2019 to eszopiclone and other prescription sleep medicines describing the risk of serious injury from complex sleep behaviors, including sleepwalking and sleep-driving, that can occur without full awareness. The FDA advises stopping the medication if a patient experiences an episode like this. Separately, the FDA has issued guidance on next-morning impairment risk with sedative-hypnotics as a class, relevant to anyone who needs to drive or operate machinery within a normal wake window after dosing. These warnings apply to eszopiclone regardless of whether the tablet is brand, generic, or compounded, and regardless of price.

Patients with known hypersensitivity to eszopiclone should not use this medication, dosing must be reduced in severe liver disease, and eszopiclone can interact with potent CYP3A4 inhibitors as well as other central nervous system depressants such as alcohol and opioid medications, according to FDA labeling. Safety information during pregnancy and breastfeeding is incomplete, and medical providers typically prefer non-medication strategies like cognitive behavioral therapy for insomnia during pregnancy when feasible. This information does not replace personalized dosing recommendations from the prescribing provider; people who develop marked daytime drowsiness, engage in sleepwalking or sleep-driving, or notice symptoms suggesting an allergic reaction should contact a healthcare provider promptly rather than changing their dose on their own.

What is established, what is plausible, and what is not established

Established: eszopiclone is FDA-approved for insomnia, is a Schedule IV controlled substance, carries a boxed warning for complex sleep behaviors and a separate warning about next-morning impairment, and generic versions have been available since patent expiration in 2014.

Plausible but not verified here: that a specific TennCare formulary status, a specific commercial insurance copay, a specific chain's cash price, or a specific compounding-pharmacy bundled price applies today. These facts exist and are knowable, but this article does not have a dated, sourced citation for any single current number, and presenting one as fact would overstate what is verified.

Not established by the evidence available: that compounded eszopiclone is clinically equivalent to the FDA-approved product, or that any particular discount program, savings card, or membership price will be available at the time a reader looks for it. Manufacturer savings cards and patient assistance program terms change on their own schedule and should be confirmed directly with the manufacturer or through a program directory such as NeedyMeds NeedyMeds.

Verification checklist: stable facts versus facts you must check today

Use this before making a purchasing or coverage decision. The left column rarely changes and can be relied on as written above. The right column changes by month, plan year, or pharmacy and must be re-verified at the time of use.

Stable, federally anchored facts (safe to rely on without re-checking):

  • Eszopiclone is the generic name; Lunesta is the brand name; both refer to the same molecule.
  • Eszopiclone is FDA-approved for insomnia and is a DEA Schedule IV controlled substance.
  • A boxed warning for complex sleep behaviors applies to eszopiclone at any dose.
  • A 503A compounding pharmacy can legally prepare individualized eszopiclone with a valid prescription, but a compounded product is not FDA-approved as a finished drug.
  • CBT-I is a guideline-supported first-line, non-drug approach to chronic insomnia.

Date-sensitive facts you must verify directly before relying on them:

  • Whether TennCare currently covers eszopiclone for insomnia, and under what prior-authorization criteria, by checking TennCare's published pharmacy preferred drug list.
  • Your specific commercial or Medicare Part D plan's current tier placement, copay, and step-therapy requirement, by calling member services or checking the current formulary document.
  • The cash price at your specific Tennessee pharmacy today, including whether a coupon changes that price, checked in person or by phone.
  • Whether a manufacturer savings card or patient assistance program is currently active and what its income or insurance eligibility rules are, confirmed directly with the manufacturer or through NeedyMeds.
  • Whether a telehealth platform's prescriber and any partnered compounding pharmacy currently hold active Tennessee licenses, checked against the Tennessee Board of Pharmacy's license lookup.
  • Current DEA telemedicine controlled-substance prescribing rules, since flexibilities adopted after the COVID-19 public health emergency have been extended on a rolling basis rather than made permanent.

If you cannot verify an item in the right-hand list from a primary source dated within the last few months, treat any number you have been given as an estimate, not a quote.

When to seek urgent care rather than adjust a dose

Contact a clinician promptly, or seek urgent care, if you experience a sleepwalking, sleep-driving, or other complex sleep behavior episode; signs of an allergic reaction; severe next-day sedation that affects your safety; or if you have taken more than your prescribed dose. Do not stop or change a controlled-substance sleep medication on your own without guidance, since abrupt changes can affect sleep and, in some cases, carry withdrawal-type effects; discuss any change with the prescribing clinician.

References

This article summarizes publicly available regulatory information and is not a substitute for individualized medical or pharmacy benefit advice. Coverage rules, prices, and program terms change and should be verified with TennCare, your insurer, your pharmacy, or the manufacturer before you make a decision. This draft is pending qualified clinical and pharmacy-benefit review before publication.